News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough
Aman Chauhan/X
Oct 20, 2023, 20:13

Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough

Aman Chauhan, Leader of Neuroendocrine Cancer Program at the Sylvester Comprehensive Cancer Center, shared on his Twitter:

“High-grade NEC is among the toughest cancers to treat. I had a great time collaborating with Dr. Anish Thomas and help in accrual for this ATRi study. Please check out our work just published in JAMA Oncology. We will continue to work on NEC and SCLC and hopefully find a breakthrough. Promising studies on the horizon. Stay tuned!! ”

For the article click here.

Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough

Source: Aman Chauhan/Twitter

Aman Chauhan Anish Thomas cancer JAMA Oncology OncoDaily Oncology SCLC
Special Coverage
Blog
Dec 30, 2024, 19:52
CelloType: A New Machine Learning Tool for Analyzing Cancer Cells and Tissues
Blog
Dec 30, 2024, 19:26
“QI Scholar Nursing Presentations Part 2” from the SIOP Nursing Network
Science
Dec 30, 2024, 13:52
Nico Gagelmann: Selected clinical studies 2024 in hematology
Insight
Dec 30, 2024, 13:43
Roupen Odabashian: When it comes to real-life cases, physicians still outperform AI
Blog
Dec 30, 2024, 13:42
Shaban Juma: The key to being one step ahead in the fight against cancer
Positive
Dec 30, 2024, 13:42
Improving the lives of children with cancer everywhere - St. Jude Children's Research Hospital
Blog
Dec 30, 2024, 13:37
Matthew Pech: The failure of ex vivo gene therapy for sickle cell and the role of the TPP in the drug development process
Insight
Dec 30, 2024, 13:35
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
Insight
Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Blog
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Insight
Dec 30, 2024, 13:23
Satya Prakash Yadav: 2024 blockbuster Menin inhibitor for infant ALL
Insight
Dec 30, 2024, 13:10
Promising response to lurbinectedin in NUT carcinoma by M.V. Sánchez Becerra et al. - Vivek Subbiah